Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
DANBURY, Conn., Dec. 17, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced a long-term supply agreement with BD (Becton, Dickinson and Company), a leading global medical technology...
-
DANBURY, Conn., Dec. 12, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) will issue its fourth quarter fiscal year 2013 financial results on December 18, 2013. Following the release of the...
-
DANBURY, Conn., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced the initiation of a Phase 1 clinical trial under its existing U.S. Investigational New Drug Application, as...
-
DANBURY, Conn., Sept. 8, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced preliminary results from Study 3-201, a Phase 2 clinical study of BIOD-123, an investigational...
-
DANBURY, Conn., Aug. 12, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today reported financial results for the third fiscal quarter ended June 30, 2013. Portfolio highlights since last fiscal...
-
DANBURY, Conn., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) announced today that management will be presenting an overview of the company's technologies, development programs, and...
-
DANBURY, Conn., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) will issue its third quarter fiscal year 2013 financial results on August 12, 2013. Following the release of the company's...
-
DANBURY, Conn., July 11, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced that all scheduled follow-up visits have been completed for patients enrolled in the Phase 2 clinical trial...
-
DANBURY, Conn., July 3, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) announced today that management will present new preclinical pharmacokinetic and pharmacodynamic data on its glucagon...
-
DANBURY, Conn., July 2, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD), a biotechnology company developing novel treatments for diabetes, announced today that the company has joined the Russell...